
AI is 'bailing out' most of the U.S. stock market, Josh Brown says
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Atombeat and BioDuro link for peptide drug discovery platform
Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery. The collaboration combines Atombeat's expertise in in silico modelling with BioDuro's capabilities in discovery chemistry, biology, and drug metabolism and pharmacokinetics. The initiative is set to enhance the development of next-generation peptides, quality candidates with quick timelines and cost-effectiveness across various therapeutic areas. Atombeat expedites the discovery of drugs using its Hermite software and RiDYMO platform, incorporating technologies such as Uni-Dock and Reinforced Dynamics. These tools enable the exploration of a digital library with over one trillion potential peptide compounds, streamlining the early drug discovery process. By focusing on the most promising candidates, the platform is designed to save cost, time and effort in drug development. BioDuro's role in the partnership is to leverage its synthesis capability for producing several peptide compounds in parallel. The company will be able to deliver pure peptides within one week, without the need for purification steps. This integrated approach aims to significantly reduce research and development timelines and associated costs and risks. BioDuro CEO Dr Armin Spura stated: 'We are excited to advance peptide innovation through our strategic partnership with Atombeat. Atombeat brings extensive experience in AI-assisted drug design and optimisation. 'Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.' The AI-accelerated platform will facilitate a seamless workflow from molecular design to preclinical candidate selection. It is expected to deliver cyclic peptides that meet key developability traits, such as membrane permeability, across a broad range of therapeutic areas. "Atombeat and BioDuro link for peptide drug discovery platform" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
8 minutes ago
- Yahoo
Amphenol to buy CommScope's broadband connectivity, cable unit for $10.5 billion
(Reuters) -Fiber-optic cable maker Amphenol said on Monday it will buy CommScope's connectivity and cable solutions business for $10.5 billion in an all-cash deal. Shares of CommScope surged 42% in premarket trading, while Amphenol rose about 2%. The transaction aims to bolster Amphenol's portfolio, particularly by adding fiber optic interconnect products for artificial intelligence and other data center applications. The deal is expected to close in the first half of 2026 and will add to Amphenol's diluted earnings per share in first full year after closing. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Big Tech's AI Spend Could Reach $400 Billion
Microsoft (NASDAQ:MSFT) and Meta (NASDAQ:META) are pushing Big Tech's AI infrastructure spend toward an estimated $400 billion, with public filings already showing $344 billion this year. The increase is funding data centers, AI ready servers and model training as Morgan Stanley sees the surge adding up to 0.5% to U.S. GDP in 2025 and 2026 and projects $2.9 trillion in related investment from 2025 to 2028. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Microsoft set a record with $24.2 billion in capex last quarter and plans more than $30 billion this quarter, while Amazon (NASDAQ:AMZN) logged $31.4 billion, and Alphabet raised its full year capex forecast to $85 billion. Meta raised the low end of 2025 guidance and is expanding its internal AI unit, signaling further planned Street has reacted unevenly: Microsoft and Meta shares climbed, with Microsoft hitting a $4 trillion value and Meta up more than 8%, while Amazon slid 8% after weak cloud results. Apple remains an outlier with $9.47 billion invested over nine months, up 45% year over year, prioritizing efficiency. This article first appeared on GuruFocus. Sign in to access your portfolio